NEWS
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury
Synaptogenix (NASDAQ: SNPX) has announced a new collaboration with LSU Health New Orleans' Neuroscience Center of Excellence to test its polyunsaturated fatty acid (PUFA) analogs for treating spinal cord injury (SCI). The company also received US Patent No. 12,016,837 for its PUFA analogs in treating neurodegenerative diseases.
The study will compare these analogs with Bryostatin in SCI treatment. Synaptogenix holds exclusive rights to these PUFA analogs, which have shown promise in earlier pre-clinical testing for various neurodegenerative diseases. Like Bryostatin-1, these analogs activate the enzyme PKC epsilon (PKC ε), but at a different site, potentially offering a next-generation treatment for neurodegenerative conditions.
The study will compare these analogs with Bryostatin in SCI treatment. Synaptogenix holds exclusive rights to these PUFA analogs, which have shown promise in earlier pre-clinical testing for various neurodegenerative diseases. Like Bryostatin-1, these analogs activate the enzyme PKC epsilon (PKC ε), but at a different site, potentially offering a next-generation treatment for neurodegenerative conditions.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2882Followers
108Following
30KVisitors
Follow